cjc-1295 no dac + ipamorelin vs sermorelin: Frequently asked questions

Discard it immediately and do not administer. Lyophilised peptides should reconstitute into clear, colorless solutions without visible particulates or cloudiness. Discoloration (yellow, brown) or clumping indicates protein denaturation—likely from temperature excursion during storage or shipping, contamination during reconstitution, or manufacturing defects. Denatured peptides lose biological activity entirely, and administering them introduces the risk of immune response to aggregated proteins without delivering any GH secretagogue effect. At Real Peptides, every peptide is synthesized through small-batch production with exact amino-acid sequencing—visual inspection post-reconstitution is the final quality checkpoint before use. If appearance is abnormal, contact the supplier for replacement rather than proceeding with compromised material.

CJC-1295/Ipamorelin administered once daily in the evening will produce greater cumulative IGF-1 elevation than Sermorelin despite identical dosing frequency. The extended GH exposure window (8–12 hours vs 60–90 minutes) allows hepatic IGF-1 synthesis to proceed through multiple transcription cycles before GH returns to baseline. However, if the research model prohibits evening administration—for example, diurnal animal models or shift-work human studies—morning administration of CJC-1295/Ipamorelin will still outperform Sermorelin for total IGF-1 AUC. The temporal alignment with sleep cycles matters more for circadian studies than for cumulative IGF-1 endpoints.

Design a crossover study with washout periods between peptide phases. Administer Sermorelin during the pulsatile measurement phase, allow a 7–10 day washout to clear any receptor adaptation, then switch to CJC-1295/Ipamorelin for the sustained phase. This approach controls for inter-subject variability by using each participant as their own control. The washout period is critical—residual receptor desensitization or elevated baseline IGF-1 from the first phase would confound measurements in the second phase. Blood sampling frequency must also differ: Sermorelin phases require dense sampling (every 15–30 minutes) to capture the sharp pulse, while CJC-1295/Ipamorelin phases can use 2–4 hour intervals since the kinetic curve changes more gradually.

Switch to an alternating protocol: 5 days on, 2 days off, or alternate between CJC-1295/Ipamorelin and Sermorelin weekly. GHRH receptor downregulation occurs with sustained supraphysiological stimulation, but the kinetics differ between peptides. Sermorelin's short pulsatile activation pattern produces less receptor internalization than sustained agonist exposure, which is why some long-duration protocols cycle between sustained (CJC/Ipamorelin) and pulsatile (Sermorelin) phases to maintain receptor sensitivity. If the research question requires uninterrupted daily administration, reduce the dose by 20–30% after week 4 and monitor GH response curves—partial dose reduction often restores sensitivity without requiring full cessation.

Switch to the CJC-1295 no DAC and Ipamorelin combination before increasing Sermorelin dose beyond 500 mcg per injection. Poor response typically indicates either rapid enzymatic degradation or insufficient endogenous GHRH receptor density at the pituitary. A limitation the ghrelin pathway can bypass. Models with blunted Sermorelin response demonstrate 60–80% improvement in GH pulse amplitude when switched to the dual-pathway stack. If the combination also fails to produce measurable IGF-1 elevation after 3–4 weeks, the issue is likely downstream rather than inadequate GH secretion.

Sermorelin monotherapy remains viable when budget or supply chain constraints make the combination stack impractical. While the combination produces higher peak GH levels, Sermorelin at proper dosing frequency still generates measurable IGF-1 elevation. The trade-off is injection frequency and handling complexity. If supply chain issues affect either peptide in the combination, do not substitute with CJC-1295 with DAC without adjusting the dosing schedule. Its multi-day half-life creates continuous rather than pulsatile GH elevation and increases receptor desensitisation risk.

Reduce the dose by 30–40% and extend the titration period rather than discontinuing immediately. Most side effects are dose-dependent and transient, resolving within 2–3 weeks. For Sermorelin, splitting the daily dose into smaller, more frequent injections often eliminates symptoms without reducing total GH output. For the combination stack, starting at 50–100 mcg of each peptide and increasing by 50 mcg every 5–7 days allows adaptation with minimal symptom burden. If symptoms persist, verify injection timing relative to meals.